Overcoming the Resistance Hurdle: Pharmacokinetic-Pharmacodynamic Target Attainment Analyses for Rezafungin (CD101) against Candida albicans and Candida glabrata
暂无分享,去创建一个
S. Flanagan | S. Bhavnani | P. Ambrose | E. Lakota | C. Rubino | T. Sandison | J. Bader | V. Ong
[1] S. Flanagan,et al. Population Pharmacokinetic Analyses for Rezafungin (CD101) Efficacy Using Phase 1 Data , 2018, Antimicrobial Agents and Chemotherapy.
[2] S. Flanagan,et al. CD101 Prophylactic Dose Rationale for Prevention of Aspergillus, Candida, and Pneumocystis Infections , 2018 .
[3] D. Andes,et al. Pharmacodynamics of a Long-Acting Echinocandin, CD101, in a Neutropenic Invasive-Candidiasis Murine Model Using an Extended-Interval Dosing Design , 2017, Antimicrobial Agents and Chemotherapy.
[4] C. Pillar,et al. In vitro potency and fungicidal activity of CD101, a novel echinocandin, against recent clinical isolates of Candida spp. , 2017, Diagnostic microbiology and infectious disease.
[5] M. Castanheira,et al. CD101, a long-acting echinocandin, and comparator antifungal agents tested against a global collection of invasive fungal isolates in the SENTRY 2015 Antifungal Surveillance Program. , 2017, International journal of antimicrobial agents.
[6] Paul G. Ambrose,et al. Pharmacological Basis of CD101 Efficacy: Exposure Shape Matters , 2017, Antimicrobial Agents and Chemotherapy.
[7] M. Castanheira,et al. Activity of a Long-Acting Echinocandin (CD101) and Seven Comparator Antifungal Agents Tested against a Global Collection of Contemporary Invasive Fungal Isolates in the SENTRY 2014 Antifungal Surveillance Program , 2017, Antimicrobial Agents and Chemotherapy.
[8] D. Thye,et al. Safety and Pharmacokinetics of CD101 IV, a Novel Echinocandin, in Healthy Adults , 2016, Antimicrobial Agents and Chemotherapy.
[9] M. Desnos-Ollivier,et al. Recurrent episodes of Candidemia due to Candida glabrata, Candida tropicalis and Candida albicans with acquired echinocandin resistance , 2016, Medical mycology case reports.
[10] C. Duvoux,et al. Echinocandin Resistance in Candida Species Isolates from Liver Transplant Recipients , 2016, Antimicrobial Agents and Chemotherapy.
[11] J. Balkovec,et al. Preclinical Evaluation of the Stability, Safety, and Efficacy of CD101, a Novel Echinocandin , 2016, Antimicrobial Agents and Chemotherapy.
[12] Jeffrey B Locke,et al. Characterization of In Vitro Resistance Development to the Novel Echinocandin CD101 in Candida Species , 2016, Antimicrobial Agents and Chemotherapy.
[13] Ronald N. Jones,et al. Activity of a long-acting echinocandin, CD101, determined using CLSI and EUCAST reference methods, against Candida and Aspergillus spp., including echinocandin- and azole-resistant isolates , 2016, The Journal of antimicrobial chemotherapy.
[14] J. Sobel,et al. Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. , 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[15] J. Sobel,et al. Executive Summary: Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. , 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[16] E. Mellado,et al. Rapid Development of Candida krusei Echinocandin Resistance during Caspofungin Therapy , 2015, Antimicrobial Agents and Chemotherapy.
[17] D. Perlin. Echinocandin Resistance, Susceptibility Testing and Prophylaxis: Implications for Patient Management , 2014, Drugs.
[18] K. Garey,et al. FKS mutant Candida glabrata: risk factors and outcomes in patients with candidemia. , 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[19] J. Topal,et al. Development of echinocandin‐resistant Candida albicans candidemia following brief prophylactic exposure to micafungin therapy , 2014, Transplant infectious disease : an official journal of the Transplantation Society.
[20] K. Kuchler,et al. Positions and Numbers of FKS Mutations in Candida albicans Selectively Influence In Vitro and In Vivo Susceptibilities to Echinocandin Treatment , 2014, Antimicrobial Agents and Chemotherapy.
[21] P. Biswas,et al. Evaluation of an early step-down strategy from intravenous anidulafungin to oral azole therapy for the treatment of candidemia and other forms of invasive candidiasis: results from an open-label trial , 2014, BMC Infectious Diseases.
[22] A. Colombo,et al. An open‐label study of anidulafungin for the treatment of candidaemia/invasive candidiasis in Latin America , 2014, Mycoses.
[23] B. Wickes,et al. Rapid Emergence of Echinocandin Resistance in Candida glabrata Resulting in Clinical and Microbiologic Failure , 2013, Antimicrobial Agents and Chemotherapy.
[24] C. Clancy,et al. Caspofungin MICs Correlate with Treatment Outcomes among Patients with Candida glabrata Invasive Candidiasis and Prior Echinocandin Exposure , 2013, Antimicrobial Agents and Chemotherapy.
[25] C. Clancy,et al. The Presence of an FKS Mutation Rather than MIC Is an Independent Risk Factor for Failure of Echinocandin Therapy among Patients with Invasive Candidiasis Due to Candida glabrata , 2012, Antimicrobial Agents and Chemotherapy.
[26] G. Auzinger,et al. Anidulafungin for the treatment of candidaemia/invasive candidiasis in selected critically ill patients , 2012, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.
[27] F. Grenouillet,et al. Candida spp. with Acquired Echinocandin Resistance, France, 2004–2010 , 2012, Emerging infectious diseases.
[28] A. Shorr,et al. Anidulafungin compared with fluconazole for treatment of candidemia and other forms of invasive candidiasis caused by Candida albicans : a multivariate analysis of factors associated with improved outcome , 2016 .
[29] D. Andes,et al. Use of Pharmacokinetic-Pharmacodynamic Analyses To Optimize Therapy with the Systemic Antifungal Micafungin for Invasive Candidiasis or Candidemia , 2011, Antimicrobial Agents and Chemotherapy.
[30] D. Lambrechts,et al. Oral presentations , 2010, Annals of Microbiology.
[31] A. Zaas,et al. Breakthrough Invasive Candidiasis in Patients on Micafungin , 2010, Journal of Clinical Microbiology.
[32] D. Kontoyiannis,et al. Caspofungin-non-susceptible Candida isolates in cancer patients. , 2010, The Journal of antimicrobial chemotherapy.
[33] J. Cleary,et al. Effect of Candida glabrata FKS1 and FKS2 Mutations on Echinocandin Sensitivity and Kinetics of 1,3-β-d-Glucan Synthase: Implication for the Existing Susceptibility Breakpoint , 2009, Antimicrobial Agents and Chemotherapy.
[34] R. Betts,et al. A Multicenter, double-blind trial of a high-dose caspofungin treatment regimen versus a standard caspofungin treatment regimen for adult patients with invasive candidiasis. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[35] D. Perlin,et al. Correlating Echinocandin MIC and Kinetic Inhibition of fks1 Mutant Glucan Synthases for Candida albicans: Implications for Interpretive Breakpoints , 2008, Antimicrobial Agents and Chemotherapy.
[36] R. Betts,et al. Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[37] R. Betts,et al. Anidulafungin versus fluconazole for invasive candidiasis. , 2007, The New England journal of medicine.
[38] D. Pittet,et al. Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial , 2007, The Lancet.
[39] K. Marr,et al. Acquired Echinocandin Resistance in a Candida krusei Isolate Due to Modification of Glucan Synthase , 2007, Antimicrobial Agents and Chemotherapy.
[40] S. A. Parent,et al. Specific Substitutions in the Echinocandin Target Fks1p Account for Reduced Susceptibility of Rare Laboratory and Clinical Candida sp. Isolates , 2005, Antimicrobial Agents and Chemotherapy.
[41] T. Walsh,et al. A randomized, double-blind trial of anidulafungin versus fluconazole for the treatment of esophageal candidiasis. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[42] A. Llanos-Cuentas,et al. A randomized, double-blind, parallel-group, dose-response study of micafungin compared with fluconazole for the treatment of esophageal candidiasis in HIV-positive patients. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[43] G. Drusano,et al. Relationship between fluoroquinolone area under the curve: minimum inhibitory concentration ratio and the probability of eradication of the infecting pathogen, in patients with nosocomial pneumonia. , 2004, The Journal of infectious diseases.
[44] J. Perfect,et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. , 2002, The New England journal of medicine.
[45] G. Drusano,et al. Levofloxacin Population Pharmacokinetics and Creation of a Demographic Model for Prediction of Individual Drug Clearance in Patients with Serious Community-Acquired Infection , 1998, Antimicrobial Agents and Chemotherapy.
[46] W. Baginsky,et al. In Vitro Activity of 1,3-β-D-Glucan Synthase Requires the GTP-binding Protein Rho1* , 1996, The Journal of Biological Chemistry.
[47] Jerome J. Schentag,et al. Development of a population pharmacokinetic model and optimal sampling strategies for intravenous ciprofloxacin , 1993, Antimicrobial Agents and Chemotherapy.
[48] Peter L. Bonate,et al. Nonlinear Mixed Effects Models: Practical Issues , 2011 .
[49] Peter L. Bonate,et al. Pharmacokinetic-Pharmacodynamic Modeling And Simulation , 2005 .